Article
Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement.
JAMA oncology - 1 Sept 2024
Hamidi Sarah, Dadu Ramona, Zafereo Mark E, Ferrarotto Renata, Wang Jennifer R, Maniakas Anastasios, Gunn G Brandon, Lee Anna, Spiotto Michael T, Iyer Priyanka C, Sousa Luana G, Akhave Neal S, Ahmed Salmaan, Learned Kim O, Lu Charles, Lai Stephen Y, Williams Michelle, Hosseini S Mohsen, Busaidy Naifa L, Cabanillas Maria E
Abstract excerpt
Importance: BRAF/MEK inhibitors revolutionized the treatment of BRAF V600E-variant anaplastic thyroid carcinoma (BRAFv-ATC), offering improved outcomes for patients with this previously incurable disease. Observations: Anaplastic thyroid carcinoma (ATC) accounts for approximately half of thyroid cancer-related deaths. It presents as a rapidly growing tumor that often invades locoregional structures and spreads to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.